Indeed, we demonstrated that inhibiting PP2A in MPN patients’ cells in combination with ruxolitinib is more efficient in reducing their clonogenic properties than ruxolitinib alone, indicating that the PP2A activation induced by JAK2 inhibition favors the proliferation and survival of MPN cells. This evidence concerns the gene PTPA and myeloproliferative neoplasm.